Unum therapeutics stock
WebMar 26, 2024 · CAMBRIDGE, MA, March 26, 2024 – Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates. “We recently announced the … WebMar 20, 2024 · Unum Therapeutics maintains the right to terminate the common stock purchase agreement at any time, at its discretion, without any additional cost or penalty. …
Unum therapeutics stock
Did you know?
WebUnum Therapeutics is based in Cambridge, Massachusetts. Prof Campana, who is based in Singapore, chairs Unum's Scientific Advisory Board. Unum's proprietary antibody-coupled … WebRecommended Hot Products: GMP Human IL-15 Protein DMF Filed Human CD19 (20-291) Protein, Fc Tag, premium grade DMF Filed Human BCMA / TNFRSF17 Protein, His Tag, premium grade DMF Filed ACROBiosystems has established the GMP grade facility and strict quality management system to support the clinical study of immune cell therapy.
WebAug 11, 2024 · Unum believes that its current cash and cash equivalents, including the $104.4 million received on July 9, 2024 from the Series A Preferred Stock private placement, will enable Unum to fund its ...
WebApr 4, 2024 · Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6% finance.yahoo.com - July 8 at 9:40 AM: Why Unum Therapeutics Is Trading Higher Today … WebStock price history for Unum Therapeutics. companies: 7,328 total market cap: $88.041 T. Global ranking; Ranking by countries. America 🇺🇸 United States 🇨🇦 Canada 🇲🇽 Mexico 🇧🇷 Brazil 🇨🇱 …
WebJul 6, 2024 · On average, analysts give Unum Therapeutics Inc a Sell rating. The average price target is $1, which means analysts expect the stock to fall by -43.18% over the next twelve months. That average ranking earns Unum Therapeutics Inc an Analyst Rating of 7, which is better than 7% of stocks based on data compiled by InvestorsObserver.
WebApr 13, 2024 · The fund owned 26,500 shares of the biopharmaceutical company’s stock after selling 17,500 shares during the quarter. Strs Ohio’s holdings in Halozyme Therapeutics were worth $1,507,000 as of ... twirp thriftWebThe forward PE ratio stands at 18.05, which indicates stocks potential in earnings. HE's price-to-sales ratio (TTM) is 1.268, and the price-to-book ratio is 2.074. The company's enterprise value-to-revenue and enterprise value-to-EBITDA ratios are 1.518 and 7.75, respectively. HE Stock Stability: Analyzing Marketing Volatility and Trends twis as nice store in scWebThe market cap of Unum Therapeutics Inc is $105.32M. What is the 52 week high for Unum Therapeutics Inc? ... What is the 52 week low for Unum Therapeutics Inc? The 52 week … take a break monthly competitionsWebAug 11, 2024 · Unum believes that its current cash and cash equivalents, including the $104.4 million received on July 9, 2024 from the Series A Preferred Stock private … take a break march 2023 answersWebAgreement and Plan of Merger . On July 6, 2024, Unum Therapeutics Inc., a Delaware corporation (“Unum”), completed its business combination with Kiq Bio LLC (formerly Kiq … twirrewyn light regularWebUnum Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Unum Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: … take a break monthlyWebApr 13, 2024 · In other Karuna Therapeutics news, insider Stephen K. Brannan sold 5,000 shares of the business’s stock in a transaction on Monday, April 10th. The shares were sold at an average price of $176. ... take a break october